Who is sponsoring NCT04356066?

NCT04356066 is sponsored by Assiut University.

What drugs are being tested in NCT04356066?

Interventions in NCT04356066: serum cxcl10 by ELISA.

What condition does NCT04356066 study?

NCT04356066 studies Interstitial Lung Disease in Patients With Rheumatoid Arthritis.

Is NCT04356066 still recruiting?

NCT04356066 is currently status unknown. Last updated 22 April 2020.

Last reviewed 2020-04-22 · How we verify

NCT04356066

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CXCL10 As a Biomarker Of ILD in Patients WithRA

Status unknown NA Last updated 22 April 2020

What this trial tests

NA trial testing serum cxcl10 by ELISA in Interstitial Lung Disease in Patients With Rheumatoid Arthritis in 80 participants. Status unknown.

Timeline

19 December 2020

Primary endpoint
19 January 2021

19 January 2022

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	80
Start date	19 December 2020
Primary completion	19 January 2021
Estimated completion	19 January 2022

Drugs / interventions tested

serum cxcl10 by ELISA

Conditions studied

Interstitial Lung Disease in Patients With Rheumatoid Arthritis — all drugs for Interstitial Lung Disease in Patients With Rheumatoid Arthritis →

Sponsor

Assiut University

Who can join

Adults 18 to 80, any sex, with Interstitial Lung Disease in Patients With Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rheumatoid arthritis is a chronic inﬂammatory disease that affects the joints, causing symmetric pain, stiffness, swelling, and limited motion and function of multiple joints, its ﬁbro inﬂammatory manifestations may develop in other organs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Interstitial Lung Disease in Patients With Rheumatoid Arthritis

Currently open trials in the same condition.

NCT06965322 — Study on the Detection of Pleuropulmonary Manifestations in Rheumatoid Arthritis · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04356066 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 22 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04356066.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing